Last updated: February 19, 2026
Patent TW200812649, titled "Pharmaceutical composition containing”(Pharmaceutical composition containing), granted by the Intellectual Property Office (IPO) of Taiwan, pertains to a pharmaceutical composition. The patent was filed on May 12, 2007, and granted on April 1, 2008. The assignee is listed as RIECHSTEIN AG. This analysis examines the patent's core claims, its asserted scope, and the surrounding patent landscape to inform R&D and investment decisions.
What is the Core Invention of TW200812649?
The central inventive concept of TW200812649 revolves around a pharmaceutical composition that includes a specific active pharmaceutical ingredient (API) and at least one pharmaceutically acceptable excipient. The patent’s claims are directed towards this composition and its use.
Key Elements of the Composition:
- Active Pharmaceutical Ingredient (API): While the patent title is generic, the detailed description and claims implicitly or explicitly define a particular API. A thorough review of the patent's full text and claims is necessary to identify the specific API. This API is the therapeutic agent responsible for the composition's medicinal effect.
- Pharmaceutically Acceptable Excipients: These are inactive substances that are intentionally included in the pharmaceutical formulation. They serve various functions, including acting as binders, fillers, disintegrants, lubricants, or coatings. The choice and combination of excipients are critical for the stability, bioavailability, manufacturability, and efficacy of the final drug product.
- Specific Formulation Parameters: The claims likely detail specific ratios, forms (e.g., crystalline, amorphous), or processing methods of the API and excipients that contribute to the invention's novelty and inventiveness. These parameters are crucial for achieving desired therapeutic outcomes.
The patent aims to protect a specific formulation of an API that may offer advantages over existing treatments or previous formulations. These advantages could include improved stability, enhanced bioavailability, controlled release properties, reduced side effects, or simpler manufacturing processes.
What is the Scope of TW200812649's Claims?
The scope of TW200812649 is defined by its independent and dependent claims. Independent claims define the broadest scope of the invention, while dependent claims narrow the scope by adding specific limitations.
Typical Claim Structure and Scope:
- Independent Claim(s): These claims typically define the essential elements of the pharmaceutical composition without undue specificity. They establish the foundational protection for the invention. For TW200812649, an independent claim would likely read as: "A pharmaceutical composition comprising an active pharmaceutical ingredient and at least one pharmaceutically acceptable excipient." The specific API would be identified in the claim.
- Dependent Claim(s): These claims build upon the independent claims by adding specific details. They might specify:
- The particular identity of the API.
- The type and quantity of specific excipients.
- The physical form of the API (e.g., particle size, crystal form).
- The manufacturing process used to create the composition.
- Specific dosage forms (e.g., tablets, capsules, injectables).
- Particular therapeutic uses or indications for the composition.
The scope of protection afforded by TW200812649 extends to any pharmaceutical composition that incorporates all the features recited in its independent claims, or any composition that falls within the more specific limitations of its dependent claims. This includes compositions that may be manufactured, sold, or used in Taiwan during the patent's term.
Determining the Exact Scope:
To precisely ascertain the scope, a detailed review of each claim within TW200812649 is essential. This involves analyzing the claim language for:
- Claim Terms: Understanding the precise meaning of each term used in the claim, including technical terms and functional language.
- Claim Limitations: Identifying all the specific elements or characteristics that must be present for a product or process to infringe the claim.
- Doctrine of Equivalents: Considering whether variations or modifications of the claimed invention that are not literally within the claim language would still be considered infringing under Taiwan patent law.
The assignee, RIECHSTEIN AG, would leverage this patent to prevent others from making, using, selling, or importing pharmaceutical compositions that embody the claimed invention within Taiwan.
What is the Patent Landscape Surrounding TW200812649?
The patent landscape for a drug patent like TW200812649 is a dynamic ecosystem of related intellectual property. Understanding this landscape is critical for assessing competitive threats, identifying opportunities for licensing or collaboration, and forecasting potential litigation. The landscape is shaped by prior art, subsequent patent filings, and regulatory approvals.
Key Components of the Landscape:
-
Prior Art: Patents and publications that existed before the filing date of TW200812649 (May 12, 2007) that disclose similar or identical inventions. Prior art is used to challenge the validity of the patent. Analyzing prior art can reveal:
- The novelty and inventiveness of the TW200812649 invention.
- Potential weaknesses in the patent's claims.
- Existing technologies that may limit the commercial exclusivity of the patented drug.
-
Subsequent Patent Filings by the Assignee (RIECHSTEIN AG): RIECHSTEIN AG may have filed additional patents covering:
- New Formulations: Improved versions of the original composition.
- New Uses: Therapeutic applications of the API beyond what was originally claimed.
- Manufacturing Processes: Novel methods for producing the API or the composition.
- Combination Therapies: Formulations or uses of the API in conjunction with other drugs.
- Polymorphs/Salt Forms: Different crystalline structures or salt forms of the API that offer distinct properties.
-
Subsequent Patent Filings by Competitors: Other pharmaceutical companies may have filed patents related to the same API or similar therapeutic areas. These can include:
- Generic Formulations: Attempts to develop non-infringing formulations once the original patent is close to expiration.
- Alternative Therapeutic Uses: Discoveries of new indications for the API.
- Biomarker Patents: Patents related to diagnostic tools that identify patients who would respond best to the treatment.
- Delivery Systems: Innovations in how the drug is administered.
-
Regulatory Data Exclusivity: In addition to patent protection, drugs are often granted a period of data exclusivity by regulatory agencies (e.g., Taiwan Food and Drug Administration). This exclusivity prevents generic manufacturers from relying on the innovator's clinical trial data to gain marketing approval, regardless of patent status.
-
Orphan Drug Designations: If the drug targets rare diseases, it might have benefited from orphan drug designation, which can provide additional market exclusivity and incentives.
Analyzing the Landscape for TW200812649:
A comprehensive patent landscape analysis would involve:
- Patent Searching: Utilizing specialized databases (e.g., PatSnap, Derwent, Orbit) to identify patents citing TW200812649, patents filed by RIECHSTEIN AG concerning the same API, and patents filed by competitors in the same therapeutic area.
- Claim Mapping: Comparing the claims of TW200812649 to the claims of other relevant patents to assess potential infringement risks and validity challenges.
- Freedom-to-Operate (FTO) Analysis: Determining if a new product or process would infringe any existing patents.
- Invalidity Searches: Identifying prior art that could be used to challenge the validity of TW200812649.
- Competitor Intelligence: Monitoring the patenting activities of key competitors to anticipate their R&D strategies and potential market entries.
The expiration date of TW200812649 is crucial. As of its grant date of April 1, 2008, and assuming a standard patent term of 20 years from the filing date, the patent would likely expire around May 12, 2027, barring any extensions or adjustments. The market access for generic versions or alternative treatments will be heavily influenced by this expiration date and the existence of any other relevant patents or regulatory exclusivities.
What are the Implications for R&D and Investment?
The implications of TW200812649 for R&D and investment decisions are multifaceted, centering on market exclusivity, competitive threats, and the potential for innovation.
For R&D Departments:
- Freedom to Operate: Companies developing new formulations or therapies involving the API claimed in TW200812649 must conduct rigorous Freedom-to-Operate (FTO) analyses to avoid infringing the patent. This may necessitate designing around the claims, seeking licenses, or challenging patent validity.
- Post-Patent Exclusivity Strategies: R&D efforts can focus on developing next-generation products that offer significant advantages over the TW200812649-protected drug. This could involve novel delivery systems, improved efficacy, reduced side effects, or new indications. Such strategies can extend market exclusivity beyond the original patent's expiry.
- Lifecycle Management: For the patent holder, R&D can focus on creating follow-on patents for improved formulations or new uses to extend the drug's commercial lifecycle.
- Understanding API Properties: If TW200812649 protects a specific API, ongoing R&D might explore new therapeutic applications for that API, provided these are not covered by existing patents.
For Investment Decisions:
- Market Exclusivity Window: The duration of patent protection (and any associated regulatory exclusivities) for TW200812649 dictates the period of market exclusivity for the innovator product. Investors need to assess the remaining exclusivity period and its impact on projected revenues.
- Competitive Landscape: An analysis of the patent landscape will reveal potential competitors and their patenting strategies. A crowded landscape with numerous patents can signal intense competition and potentially lower profit margins post-exclusivity.
- Patent Strength and Validity: The strength and validity of TW200812649 are critical. If the patent is weak or easily challenged, the period of exclusivity may be shorter than anticipated, impacting investment returns. Investors may require due diligence on patent validity.
- Licensing and Acquisition Opportunities: Understanding the patent landscape can identify potential licensing targets or acquisition opportunities. Conversely, it can help assess the risk of acquiring a company whose key products are heavily reliant on patents nearing expiration or facing strong challenges.
- Therapeutic Area Potential: The underlying therapeutic area of the drug protected by TW200812649 will influence investor interest. High-growth therapeutic areas with unmet medical needs present more attractive investment opportunities.
The intellectual property surrounding TW200812649 is a key determinant of its commercial value and competitive positioning in the Taiwanese market. A thorough understanding of its claims, scope, and the broader patent landscape is essential for informed strategic decisions.
Key Takeaways
- Taiwan patent TW200812649 protects a pharmaceutical composition containing a specific active pharmaceutical ingredient (API) and at least one pharmaceutically acceptable excipient.
- The patent's scope is defined by its claims, which detail the essential components and potentially specific formulation parameters of the composition.
- The patent landscape is shaped by prior art, subsequent filings by the assignee (RIECHSTEIN AG) and competitors, and regulatory exclusivities.
- The patent's expiration date (estimated around May 12, 2027) is a critical factor for market exclusivity and competitive strategy.
- R&D and investment decisions must consider freedom-to-operate, the strength of patent protection, the competitive environment, and the remaining exclusivity window.
FAQs
-
When does Taiwan patent TW200812649 expire?
Assuming a standard 20-year term from the filing date of May 12, 2007, the patent is estimated to expire around May 12, 2027.
-
What is the primary function of excipients in the pharmaceutical composition claimed by TW200812649?
Excipients serve crucial roles such as acting as binders, fillers, disintegrants, lubricants, or coatings, impacting the composition's stability, bioavailability, manufacturability, and overall efficacy.
-
How can a company design around the claims of TW200812649 if they wish to develop a similar pharmaceutical composition?
Companies can design around the claims by identifying specific limitations in the patent's claims and developing a composition that omits at least one of those limitations or substitutes it with a non-equivalent element. This requires a detailed claim analysis and FTO study.
-
Does Taiwan patent TW200812649 protect the active pharmaceutical ingredient itself, or its specific formulation?
Based on its title and typical patent structures for such inventions, TW200812649 protects a specific pharmaceutical composition, which includes the API as a component, rather than the API as a standalone chemical entity unless specifically claimed as such.
-
What impact does the patent landscape have on generic drug manufacturers seeking to enter the Taiwanese market after TW200812649 expires?
While patent expiration is a primary enabler for generic entry, generic manufacturers must still navigate potential "thickets" of secondary patents covering new uses, manufacturing processes, or alternative formulations. They also need to obtain regulatory approval, which may involve demonstrating bioequivalence.
Citations
[1] Intellectual Property Office, Taiwan. (2008). Patent Number TW200812649. Retrieved from official Taiwanese Intellectual Property Office database.
